Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Stock Information for Bolt Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bolt Biotherapeutics Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
Bolt Biotherapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Bolt Biotherapeutics, Inc. (BOLT)
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT)
BOLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Bolt Biotherapeutics, Inc. Shareholders Who Lost Money
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Pacira Appoints Frank D. Lee as Chief Executive Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.